Roth Capital lowered the firm's price target on Insperity to $54 from $56 and keeps a Buy rating on the shares. The company's Q1 results exceeded estimates, and the firm believes that margin recovery and profit improvement in 2026 are tracking ahead of expectations, the analyst tells investors in a research note. Unit growth is challenged by higher attrition due to repricing efforts, but the profit recovery during 2026 and long-term growth potential of HRScale makes Insperity a compelling opportunity, the firm added.
